0001415889-21-003238.txt : 20210628 0001415889-21-003238.hdr.sgml : 20210628 20210628071522 ACCESSION NUMBER: 0001415889-21-003238 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210624 FILED AS OF DATE: 20210628 DATE AS OF CHANGE: 20210628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cox John CENTRAL INDEX KEY: 0001498428 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 211049931 MAIL ADDRESS: STREET 1: C/O BIOVERATIV INC. STREET 2: 225 SECOND AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 form4-06282021_070607.xml X0306 4 2021-06-24 0001821323 Sigilon Therapeutics, Inc. SGTX 0001498428 Cox John C/O SIGILON THERAPEUTICS, INC. 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 true false false false Stock Option (Right to Buy) 9.97 2021-06-24 4 A 0 8888 9.97 A 2031-06-23 Common Stock 8888 8888 D The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022. /s/ Matthew Kowalsky, Attorney-in-Fact 2021-06-28